Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
Revenue Q4 2024 $1.6 billion, up 8.3% underlying growth (7.8% reported growth) year-over-year, driven by strong December performance and two additional trading days.
Revenue Full Year 2024 $5.8 billion, up 5.3% underlying growth (4.7% reported growth) year-over-year, with all segments contributing significantly.
Gross Profit $4.09 billion with a gross margin of 70.3%, down 40 basis points year-over-year due to price impacts from joint repair VBP in China.
Trading Profit $1.05 billion, up 8.2% year-over-year, with trading margin expansion of 60 basis points to 18.1%.
Adjusted Earnings Per Share $0.843, up 1.7% year-over-year, impacted by higher tax and interest expenses.
IFRS Earnings Per Share $0.472, grew significantly due to lower restructuring charges and costs from the completed EU MDR program.
Free Cash Flow $551 million, improved due to lower restructuring costs and better cash generation.
Net Debt $2.7 billion, decreased by $67 million year-over-year.
Cash Conversion Rate 95%, ahead of target and significantly improved from 65% in 2023.
Return on Invested Capital (ROIC) 7.4%, improved by 150 basis points year-over-year, with expectations to exceed cost of capital in 2025.
Trading Margin Expansion 60 basis points year-over-year, driven by operational savings and revenue leverage.
Cost Savings from 12-Point Plan Total gross cost savings expected between $325 million and $375 million, with annualized benefits of $239 million.
Headcount Reduction 9% overall reduction, contributing to operational savings.
Inventory Days 507 days, improved by 23 days year-over-year.
New Product Launches: In 2024, over 60% of revenue growth came from products launched in the last five years, with significant contributions from CORI and AETOS shoulder.
Innovation in Existing Products: CORI has added 10 new features since 2022, and Regeneten has received 510(k) clearance for use in extra-articular ligament repair.
New Platforms: AETOS Shoulder and CATALYSTEM were launched, with plans for a stemless implant in 2025.
Digital Capabilities: Next-generation digital products are being developed, including video-based navigation for arthroscopic procedures.
IM Nails Development: New generation IM nails for trauma are in development, targeting a $1.3 billion global market.
Market Growth: Overall revenue growth for 2024 was 5.3%, with expectations of around 5% growth for 2025.
US Market Performance: US recon business showed 11.9% growth in Q4, with expectations for continued improvement.
China Market Challenges: China posed a 280 basis point headwind to group growth in Q4, with ongoing challenges expected in 2025.
Cost Savings: Total gross cost savings are expected to be between $325 million and $375 million, with significant savings from manufacturing and procurement.
Headcount Reduction: Headcount reduced by around 9% overall, with further reductions expected in 2025.
Cash Generation: Free cash flow improved to $551 million in 2024, with expectations to exceed $600 million in 2025.
12-Point Plan: The 12-Point Plan has been fully embedded, driving operational improvements and accountability across the organization.
Organizational Restructuring: Transitioned to a global business unit model to enhance accountability and commercial execution.
Future Outlook: Expect continued margin expansion in 2025 and beyond, with a trading margin target of 19% to 20%.
China Market Headwinds: China cost 280 basis points of group growth in Q4, with continued headwinds expected in 2025 due to VBP pricing impacting both Orthopedics and Sports Medicine.
Supply Chain Challenges: Significant supply chain challenges were noted, particularly affecting the recon business, which took time to improve.
Inflation and Cost Pressures: The company faced almost 700 basis points of headwinds from inflation and other external factors, which impacted profitability despite revenue growth.
Regulatory Issues: The implementation of VBP pricing in China is expected to create a sales headwind of around $25 million in 2025.
Operational Changes and Restructuring: The company has reduced its headcount by around 9% and closed four orthopedic facilities, which may impact operational capacity in the short term.
Economic Factors: The overall economic environment, including inflation and market conditions, has posed challenges that the company has had to navigate.
12-Point Plan: The 12-Point Plan is delivering financial outcomes, with operational and commercial actions leading to higher growth and margin expansion.
Cost Savings: Total gross cost savings are expected to be between $325 million and $375 million, with a focus on manufacturing and procurement.
Global Business Unit Model: Transition to a global business unit model to enhance accountability and commercial execution.
Innovation: Over 60% of revenue growth in 2024 came from products launched in the last five years, indicating a strong innovation pipeline.
Revenue Growth: Expecting revenue growth of around 5% for 2025.
Trading Margin: Guidance for trading margin expansion to between 19% and 20% in 2025.
Free Cash Flow: Expected improvement in free cash flow to over $600 million in 2025.
Return on Invested Capital (ROIC): ROIC expected to return above cost of capital in 2025.
Full Year Dividend: The proposed full year dividend is unchanged at $0.375 per share.
Cost Savings from 12-Point Plan: Total gross cost savings are now expected to be between $325 million and $375 million.
Share Buyback Consideration: The financial return on share buybacks is a relevant hurdle for M&A.
Free Cash Flow: Free cash flow improved to $551 million, with expectations to exceed $600 million in 2025.
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
The earnings call reflects mixed signals: Financial performance shows growth but is hampered by challenges in China, affecting margins and revenue outlook. The Q&A highlights uncertainties about recovery in key markets and competitive pressures. Despite some positive developments in product feedback and growth outside China, the lack of share buybacks and flat dividend policy suggest cautious financial health management. Overall, the market reaction is likely neutral, balancing growth prospects with significant regional headwinds and strategic uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
